Halyna Pylypenko
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
Papers in
- Genetics 15
- Myeloproliferative Neoplasms: Diagnosis and Treatment 9
- Chronic Lymphocytic Leukemia Research 7
-
- Lymphoma Diagnosis and Treatment 13
- Co-authors
- Sebastian Grosicki (12 shared papers)Helgi van de Velde (7 shared papers)Tadeusz Robak (7 shared papers)Xavier Leleu (6 shared papers)William Deraedt (3 shared papers)Philippe Moreau (3 shared papers)Bertrand Arnulf (2 shared papers)Huaibao Feng (2 shared papers)
In The Last Decade
Halyna Pylypenko
29 papers receiving 1.4k citations
Halyna Pylypenko's Hit Papers
Peers
Comparison fields: 5 of 65
- Hematology 710
- Genetics 354
- Oncology 584
- Pathology and Forensic Medicine 328
- Molecular Biology 654
Countries citing papers authored by Halyna Pylypenko
This map shows the geographic impact of Halyna Pylypenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Halyna Pylypenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Halyna Pylypenko more than expected).
Fields of papers citing papers by Halyna Pylypenko
This network shows the impact of papers produced by Halyna Pylypenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Halyna Pylypenko. The network helps show where Halyna Pylypenko may publish in the future.
Co-authors
The 25 scholars most cited alongside Halyna Pylypenko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Hit paper breakdown → | 2011 | 692 |
| 2 | 2015 | 274 | |
| 3 | 2015 | 158 | |
| 4 | 2012 | 92 | |
| 5 | 2016 | 23 | |
| 6 | 2020 | 22 | |
| 7 | 2020 | 20 | |
| 8 | 2018 | 15 | |
| 9 | 2015 | 15 | |
| 10 | 2021 | 12 | |
| 11 | 2020 | 10 | |
| 12 | 2017 | 10 | |
| 13 | 2012 | 8 | |
| 14 | 2016 | 8 | |
| 15 | 2010 | 5 | |
| 16 | 2019 | 5 | |
| 17 | 2020 | 5 | |
| 18 | IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY | 2016 | 4 |
| 19 | 2021 | 4 | |
| 20 | 2019 | 4 |
About Halyna Pylypenko
Halyna Pylypenko is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Hematology and Rheumatology, having authored 31 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers), Multiple Myeloma Research and Treatments (7 papers), Chronic Lymphocytic Leukemia Research (7 papers), Eosinophilic Disorders and Syndromes (7 papers), Cytokine Signaling Pathways and Interactions (4 papers), Protein Degradation and Inhibitors (3 papers) and Viral-associated cancers and disorders (3 papers). The work is most often cited by research in Hematology (710 citations), Genetics (354 citations), Oncology (584 citations), Pathology and Forensic Medicine (328 citations) and Molecular Biology (654 citations). Halyna Pylypenko has collaborated with scholars based in Czechia, Poland and Ukraine. Frequent co-authors include Sebastian Grosicki, Helgi van de Velde, Tadeusz Robak, Xavier Leleu, William Deraedt, Philippe Moreau, Bertrand Arnulf, Huaibao Feng, Grigoriy Rekhtman and Zvenyslava Masliak. Their work appears in journals such as Blood, Journal of Clinical Oncology, Haematologica, HemaSphere and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.